Table 2.
Results of univariable and multivariable analyses of risk factors for HCC development in patients treated with entecavir for CHB (N=102)
| Univariable HR (95% CI) | P-value | Multivariable HR (95% CI) | P-value | |
|---|---|---|---|---|
| Age ≥60 years | 2.48 (0.48-12.82) | 0.277 | ||
| Men | 1.29 (0.25-6.64) | 0.763 | ||
| Total bilirubin ≥1.2 mg/dL | 0.98 (0.19-5.08) | 0.981 | ||
| AST ≥120 U/L | 0.39 (0.47-3.25) | 0.384 | ||
| ALT ≥120 U/L | 0.25 (0.30-2.06) | 0.197 | ||
| Albumin <4.0 g/dL | 3.00 (0.67-13.40) | 0.151 | ||
| Gamma-glutamyl transpeptidase ≥50 IU/L | 3.84 (0.46-31.89) | 0.214 | ||
| Platelet count <120×103/mm3 | 5.21 (1.16-23.29) | 0.031 | ||
| Ascites | 4.84 (0.94-25.09) | 0.060 | ||
| HBeAg negativity | 5.61 (1.09-28.92) | 0.039 | 4.84 (0.94-25.05) | 0.060 |
| HBV DNA ≥1 x107 IU/mL | 0.18 (0.02-1.50) | 0.113 | ||
| Child-Pugh class B or C | 2.62 (0.32-21.81) | 0.372 | ||
| Liver cirrhosis | 10.26 (1.23-85.50) | 0.031 | 9.07 (1.09-75.69) | 0.042 |
| DM / Dyslipidemia / HTN / MS | 0.28 (0.03-2.35) | 0.242 | ||
| Body mass index ≥25 kg/m2 | 0.90 (0.17-4.62) | 0.894 | ||
| Waist circumference ≥90 cm (men) or ≥80 cm (women) | 0.88 (0.17-4.53) | 0.879 | ||
| Waist-to-hip ratio ≥0.9 | 1.94 (0.23-15.87) | 0.386 | ||
| Visceral fat area ≥100 cm2 | 1.69 (0.43-8.71) | 0.495 | ||
| Hepatic steatosis on ultrasonography | 0.57 (0.07-4.74) | 0.602 |
HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; HR, hazard ratio; CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DM, diabetes mellitus; HTN, hypertension; MS, metabolic syndrome.